Skip to content

Hepatitis C co-infection increases risk of many AIDS-defining illnesses

Hepatitis B vaccine scale-up and treatment of HIV/HBV co-infection present challenges

Sustained response to interferon improves fibrosis in HIV/HCV co-infected patients

Combinations and conundrums: the challenges of hepatitis C treatment

Hepatitis B co-infection doesn't affect response to HIV treatment

Hepatitis C increases risk of cardiovascular disease

New hepatitis C drug may halve the length of treatment, but ribavirin still needed

Should we spare the nukes? NRTI HIV drugs may impair success of hepatitis C treatment

Hepatitis B hasn’t gone away – and may come back